These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. An evaluation of criteria for polymyalgia rheumatica. Bird HA; Esselinckx W; Dixon AS; Mowat AG; Wood PH Ann Rheum Dis; 1979 Oct; 38(5):434-9. PubMed ID: 518143 [TBL] [Abstract][Full Text] [Related]
25. Patient-reported outcomes in trials of patients with polymyalgia rheumatica: a systematic literature review. Huang A; Castrejon I Rheumatol Int; 2016 Jul; 36(7):897-904. PubMed ID: 26769433 [TBL] [Abstract][Full Text] [Related]
27. "An impediment to living life": why and how should we measure stiffness in polymyalgia rheumatica? Mackie SL; Hughes R; Walsh M; Day J; Newton M; Pease C; Kirwan J; Morris M PLoS One; 2015; 10(5):e0126758. PubMed ID: 25955770 [TBL] [Abstract][Full Text] [Related]
28. Usefulness of the disease activity scores for polymyalgia rheumatica for predicting glucocorticoid dose changes: a study of 243 scenarios. Binard A; De Bandt M; Berthelot JM; Saraux A; Arthritis Rheum; 2007 Apr; 57(3):481-6. PubMed ID: 17394219 [TBL] [Abstract][Full Text] [Related]
29. The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome. Muller S; Hider S; Helliwell T; Partington R; Mallen C Reumatismo; 2018 Mar; 70(1):23-34. PubMed ID: 29589400 [TBL] [Abstract][Full Text] [Related]
30. Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management. Schmidt J; Warrington KJ Drugs Aging; 2011 Aug; 28(8):651-66. PubMed ID: 21812500 [TBL] [Abstract][Full Text] [Related]
31. Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica. Owen CE; McMaster C; Liew DFL; Leung JL; Scott AM; Buchanan RRC Int J Rheum Dis; 2021 Jan; 24(1):56-62. PubMed ID: 33043616 [TBL] [Abstract][Full Text] [Related]
32. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT). Leeb BF; Bird HA; Nesher G; Andel I; Hueber W; Logar D; Montecucco CM; Rovensky J; Sautner J; Sonnenblick M Ann Rheum Dis; 2003 Dec; 62(12):1189-94. PubMed ID: 14644857 [TBL] [Abstract][Full Text] [Related]
33. Validity of the polymyalgia rheumatica activity score in primary care practice. Binard A; Lefebvre B; De Bandt M; Berthelot JM; Saraux A; Ann Rheum Dis; 2009 Apr; 68(4):541-5. PubMed ID: 18477738 [TBL] [Abstract][Full Text] [Related]
34. Predicting the risk of relapse in polymyalgia rheumatica: novel insights. Prieto-Peña D; Castañeda S; Atienza-Mateo B; Blanco R; González-Gay MA Expert Rev Clin Immunol; 2021 Mar; 17(3):225-232. PubMed ID: 33570454 [TBL] [Abstract][Full Text] [Related]
36. Challenges of diagnosing and managing polymyalgia rheumatica: a multi-methods study in UK general practice. Helliwell T; Muller S; Hider SL; Zwierska I; Lawton S; Richardson J; Mallen C Br J Gen Pract; 2018 Nov; 68(676):e783-e793. PubMed ID: 30348883 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Devauchelle-Pensec V; Berthelot JM; Cornec D; Renaudineau Y; Marhadour T; Jousse-Joulin S; Querellou S; Garrigues F; De Bandt M; Gouillou M; Saraux A Ann Rheum Dis; 2016 Aug; 75(8):1506-10. PubMed ID: 26929219 [TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Hutchings A; Hollywood J; Lamping DL; Pease CT; Chakravarty K; Silverman B; Choy EH; Scott DG; Hazleman BL; Bourke B; Gendi N; Dasgupta B Arthritis Rheum; 2007 Jun; 57(5):803-9. PubMed ID: 17530680 [TBL] [Abstract][Full Text] [Related]
39. Polymyalgia rheumatica: clinical picture and principles of treatment. Zimmermann-Górska I Pol Arch Med Wewn; 2008 Jun; 118(6):377-80. PubMed ID: 18619195 [TBL] [Abstract][Full Text] [Related]